IRWD (Ironwood Pharmaceuticals, Inc. - Class A)
Insider Trading Activity
Every open-market purchase and sale reported by IRWD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-22 | Jeffrey Silber | SVP, CMO, Head-Res&Drug | A | — | — |
| 2026-07-09 | Ronald Silver | PFO & PAO | Sell | — | — |
| 2026-06-17 | Jon R Duane | Director | A | — | — |
| 2026-06-17 | Mark G Currie | Director | A | — | — |
| 2026-06-17 | Catherine Moukheibir | Director | A | — | — |
| 2026-06-17 | Julie McHugh | Director | MIXED | — | — |
| 2026-06-17 | Jay Shepard | Director | A | — | — |
| 2026-06-17 | Marla L Kessler | Director | A | — | — |
| 2026-06-17 | ALEXANDER J DENNER | Director | A | — | — |
| 2026-05-21 | Ronald Silver | PFO & PAO | A | — | — |
| 2026-03-17 | ALEXANDER J DENNER | Director | MIXED | — | — |
| 2026-03-12 | Minardo John | Chief Legal Officer | A | — | — |
| 2026-03-12 | Michael Shetzline | SVP, CMO, Head-Res&Drug | A | — | — |
| 2026-03-12 | Tammi L Gaskins | Chief Commercial Officer | A | — | — |
| 2026-03-12 | Gregory S. Martini | Chief Financial Officer | A | — | — |
| 2026-03-12 | Thomas A MCCOURT | Chief Executive Officer | A | — | — |
| 2026-03-12 | Ronald Silver | Principal Accounting Officer | A | — | — |
| 2026-02-25 | Thomas A MCCOURT | Chief Executive Officer | Sell | — | — |
| 2026-02-25 | Tammi L Gaskins | Chief Commercial Officer | Sell | — | — |
| 2026-02-25 | Ronald Silver | Principal Accounting Officer | Sell | — | — |
| 2026-02-25 | Minardo John | Chief Legal Officer | Sell | — | — |
| 2026-02-25 | Michael Shetzline | SVP, CMO, Head-Res&Drug | Sell | — | — |
| 2026-02-25 | Gregory S. Martini | Chief Financial Officer | Sell | — | — |
| 2026-01-07 | Ronald Silver | Principal Accounting Officer | Sell | — | — |
| 2025-12-17 | ALEXANDER J DENNER | Director | A | — | — |
| 2025-11-19 | Tammi L Gaskins | Chief Commercial Officer | Sell | — | — |
| 2025-09-17 | ALEXANDER J DENNER | Director | A | — | — |
| 2025-08-13 | Ronald Silver | Principal Accounting Officer | Sell | — | — |
| 2025-08-13 | Tammi L Gaskins | Chief Commercial Officer | Sell | — | — |
| 2025-08-13 | Gregory S. Martini | Chief Financial Officer | Sell | — | — |
| 2025-08-13 | Minardo John | Chief Legal Officer | Sell | — | — |
| 2025-06-17 | ALEXANDER J DENNER | Director | A | — | — |
| 2025-06-12 | Jon R Duane | Director | A | — | — |
| 2025-06-12 | Catherine Moukheibir | Director | A | — | — |
| 2025-06-12 | Marla L Kessler | Director | A | — | — |
| 2025-06-12 | Mark G Currie | Director | A | — | — |
| 2025-06-12 | Jay Shepard | Director | A | — | — |
| 2025-06-12 | Andrew Dreyfus | Director | A | — | — |
| 2025-06-12 | Sarissa Capital Management LP | 10%+ Owner | A | — | — |
| 2025-06-12 | Julie McHugh | Director | A | — | — |
| 2025-05-20 | Tammi L Gaskins | Chief Commercial Officer | Sell | — | — |
| 2025-05-20 | Thomas A MCCOURT | Chief Executive Officer | MIXED | — | — |
| 2025-04-04 | ALEXANDER J DENNER | Director | A | — | — |
| 2025-02-12 | Thomas A MCCOURT | Chief Executive Officer | Sell | — | — |
| 2025-02-12 | Gregory S. Martini | Chief Financial Officer | Sell | — | — |
| 2025-02-12 | Michael Shetzline | SVP, CMO, Head-Res&Drug | MIXED | — | — |
| 2025-02-12 | Ronald Silver | Principal Accounting Officer | Sell | — | — |
| 2025-02-12 | Minardo John | Chief Legal Officer | MIXED | — | — |
| 2025-01-29 | Ronald Silver | Principal Accounting Officer | A | — | — |
| 2025-01-29 | Gregory S. Martini | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 16,601,769 | — |
| — | 10%+ Owner | 9,889,262 | — |
| — | Director | 9,518,290 | — |
| — | 10%+ Owner | 6,890,068 | — |
| — | Chief Executive Officer | 2,222,216 | — |
| — | Chief Executive Officer | 1,898,838 | — |
| — | 10%+ Owner | 995,804 | — |
| — | 10%+ Owner | 837,736 | — |
| — | Director | 676,900 | — |
| — | SVP, CMO, Head-Res&Drug | 658,037 | — |
| — | Director | 545,976 | — |
| — | Chief Legal Officer | 500,498 | — |
| — | Chief Executive Officer | 470,605 | — |
| — | SVP, CFO & Treasurer | 392,616 | — |
| — | SVP, Chief Operating Officer | 376,316 | — |
| — | Chief Commercial Officer | 350,350 | — |
| — | Director | 329,149 | — |
| — | Chief Operating Officer | 329,102 | — |
| — | PFO & PAO | 313,680 | — |
| — | SVP, COO and CFO | 309,572 | — |
| — | Director | 303,026 | — |
| — | Chief Financial Officer | 297,213 | — |
| — | SVP, Chief Business Officer | 284,685 | — |
| — | Director | 281,720 | — |
| — | Chief Admin Officer & SVP | 272,172 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IRWD quote page; the site-wide leaderboard is on the insider transactions hub.